Monogenic Diabetes with GATA6 Mutations: Characterization of a Novel Family and a Comprehensive Analysis of the GATA6 Clinical and Genetics Traits
-
Published:2023-05-18
Issue:
Volume:
Page:
-
ISSN:1073-6085
-
Container-title:Molecular Biotechnology
-
language:en
-
Short-container-title:Mol Biotechnol
Author:
Yue XingORCID, Luo Yaheng, Wang Jing, Huang Debin
Abstract
AbstractMonogenic diabetes caused by GATA6 mutations were almost described as neonatal diabetes, and the phenotypic spectrum has expanded since then. Our study underscores the broad phenotypic spectrum by reporting a de novo GATA6 mutation in a family. Furthermore, we reviewed related literature to summarize the clinical and genetic characteristics of monogenic diabetes with GATA6 mutations (n = 39) in order to improve clinicians’ understanding of the disease. We conclude that the GATA6 missense mutation (c. 749G > T, p. Gly250Val) is not reported presently, characterized by adult-onset diabetes with pancreatic dysplasia and located in transcriptional activation region. Carries with GATA6 mutations (n = 55) have a variable spectrum of diabetes, ranging from neonatal (72.7%), childhood-onset (20%) to adults-onset (7.5%). 83.5% of patients with abnormal pancreatic development. Heart and hepatobillary defects are the most common abnormalities of extrapancreatic features. Most mutations with GATA6 are loss of function (LOF, 71.8%) and located in functional region. Functional studies mostly support loss-of-function as the pathophysiological mechanism. In conclusion, there are various types of diabetes with GATA6 mutations, which can also occur in adult diabetes. Phenotypic defects with GATA6 mutations are most frequently malformations of pancreas and heart. This highlights the importance of comprehensive clinical evaluation of identified carriers to evaluate their full phenotypic spectrum.
Funder
Hunan Provincial Health Commission
Publisher
Springer Science and Business Media LLC
Subject
Molecular Biology,Applied Microbiology and Biotechnology,Biochemistry,Bioengineering,Biotechnology
Reference39 articles.
1. Shepherd, M., Shields, B., Hammersley, S., Hudson, M., McDonald, T. J., Colclough, K., Oram, R. A., Knight, B., Hyde, C., Cox, J., Mallam, K., Moudiotis, C., Smith, R., Fraser, B., Robertson, S., Greene, S., Ellard, S., Pearson, E. R., & Hattersley, A. T. (2016). Systematic population screening, using biomarkers and genetic testing, identifies 2.5% of the U.K. pediatric diabetes population with monogenic diabetes. Diabetes Care, 39(11), 1879–1888. 2. Thomas, C. C., & Philipson, L. H. (2015). Update on diabetes classification. Medical Clinics of North America, 99(1), 1–16. 3. De Franco, E., Flanagan, S. E., Al-Houghton, J., Allen, H. L., Mackay, D. J. G., Temple, I. K., Ellard, S., & Hattersley, A. T. (2015). The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: An international cohort study. The Lancet., 386(9997), 957–963. 4. Rubio-Cabezas, O., Hattersley, A. T., Njølstad, P. R., Mlynarski, W., Ellard, S., White, N., Chi, D. V., & Craig, M. E. (2014). ISPAD clinical practice consensus guidelines: The diagnosis and management of monogenic diabetes in children and adolescents. Pediatric Diabetes, 15(20), 47–64. 5. Shields, B. M., Hicks, S., Shepherd, M. H., Colclough, K., Hattersley, A. T., & Ellard, S. (2010). Maturity-onset diabetes of the young (MODY): How many cases are we missing? Diabetologia, 53(12), 2504–2508.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|